Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)
Publication date
2025-01
Authors
Simpson, Eric
Fernández-Peñas, Pablo
de Bruin-Weller, Marjolein
Lio, Peter A.
Chu, Chia Yu
Ezzedine, Khaled
Agell, Helena
Casillas, Marta
Ding, Yuxin
Yang, Fan Emily
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
cc_by_nc
Abstract
The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment. Corresponding values and percent improvements from baseline in EASI, Pruritus NRS, POEM, and DLQI are listed below each photo.
Keywords
Pharmacology (medical)
Citation
Simpson, E, Fernández-Peñas, P, de Bruin-Weller, M, Lio, P A, Chu, C Y, Ezzedine, K, Agell, H, Casillas, M, Ding, Y, Yang, F E, Pierce, E & Bieber, T 2025, 'Correction to : Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)', Advances in Therapy, vol. 42, no. 1, pp. 144-145. https://doi.org/10.1007/s12325-024-03010-9